New drug combo aims to cut nausea in weight loss treatments

NCT ID NCT07411560

Recruiting now Symptom relief Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing whether combining two experimental weight loss drugs—cagrilintide and a GIP receptor agonist—causes fewer stomach side effects like nausea and vomiting compared to taking cagrilintide alone. About 100 women who are overweight or obese will receive both drugs in one period and cagrilintide plus a placebo in another. The study lasts about 4.5 months and focuses on safety and tolerability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cagrilintide and NNC0480-0389 (a GIP receptor agonist)
What this could lead to: If successful, this could lead to a more tolerable weight loss drug combination with fewer stomach side effects.
What could go wrong: This is a very early Phase 1 trial with only 100 women, so results may not apply to everyone. The main goal is safety and tolerability, not weight loss, so it's too soon to know if the combo will actually help people lose weight.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESE OVERWEIGHT

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Parexel Research Unit
RECRUITING

Harrow, Middlesex, HA1 3UJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.